The impact of a rapid molecular identification test on positive blood cultures from critically ill with bacteremia: A pre-post intervention study
In this prospective study on critically ill with bloodstream infections, FA-BCID testing led to a substantial 10h02 time-reduction to administration of optimal antimicrobial treatment. This beneficial outcome was certainly a combined impact of the FA-BCID test (bioMerieux) and its around-the-clock realization covering time frames in which culture testing on positive blood bottles was limited or not realized. Thus 80% of the FA-BCID tests enabling a treatment switch occurred outside business hours and 54.3% overnight. This real-time approach has its usefulness for 24h/24 monitored critically ill but could lack clinical responsiveness overnight in other non-critical hospital units.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.